Overview

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination